Literature DB >> 16990550

Epilepsy-related ligand/receptor complex LGI1 and ADAM22 regulate synaptic transmission.

Yuko Fukata1, Hillel Adesnik, Tsuyoshi Iwanaga, David S Bredt, Roger A Nicoll, Masaki Fukata.   

Abstract

Abnormally synchronized synaptic transmission in the brain causes epilepsy. Most inherited forms of epilepsy result from mutations in ion channels. However, one form of epilepsy, autosomal dominant partial epilepsy with auditory features (ADPEAF), is characterized by mutations in a secreted neuronal protein, LGI1. We show that ADAM22, a transmembrane protein that when mutated itself causes seizure, serves as a receptor for LGI1. LGI1 enhances AMPA receptor-mediated synaptic transmission in hippocampal slices. The mutated form of LGI1 fails to bind to ADAM22. ADAM22 is anchored to the postsynaptic density by cytoskeletal scaffolds containing stargazin. These studies in rat brain indicate possible avenues for understanding human epilepsy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16990550     DOI: 10.1126/science.1129947

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  138 in total

1.  Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine-resistant breast cancer.

Authors:  Damian McCartan; Jarlath C Bolger; Aílis Fagan; Christopher Byrne; Yuan Hao; Li Qin; Marie McIlroy; Jianming Xu; Arnold D Hill; Peadar Ó Gaora; Leonie S Young
Journal:  Cancer Res       Date:  2011-11-09       Impact factor: 12.701

Review 2.  Proteomic analysis of the presynaptic active zone.

Authors:  W Volknandt; M Karas
Journal:  Exp Brain Res       Date:  2012-02-22       Impact factor: 1.972

3.  LGI1 is a Nogo receptor 1 ligand that antagonizes myelin-based growth inhibition.

Authors:  Rhalena Thomas; Kristy Favell; Jose Morante-Redolat; Madeline Pool; Christopher Kent; Melissa Wright; Kathleen Daignault; Gino B Ferraro; Samuel Montcalm; Yves Durocher; Alyson Fournier; Jordi Perez-Tur; Philip A Barker
Journal:  J Neurosci       Date:  2010-05-12       Impact factor: 6.167

4.  Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series.

Authors:  Meizan Lai; Maartje G M Huijbers; Eric Lancaster; Francesc Graus; Luis Bataller; Rita Balice-Gordon; John K Cowell; Josep Dalmau
Journal:  Lancet Neurol       Date:  2010-06-28       Impact factor: 44.182

5.  "Fold Here"-Chemical Correctors in the Treatment of Epilepsy.

Authors:  Adam L Hartman
Journal:  Epilepsy Curr       Date:  2015 Nov-Dec       Impact factor: 7.500

6.  Chemical corrector treatment ameliorates increased seizure susceptibility in a mouse model of familial epilepsy.

Authors:  Norihiko Yokoi; Yuko Fukata; Daisuke Kase; Taisuke Miyazaki; Martine Jaegle; Toshika Ohkawa; Naoki Takahashi; Hiroko Iwanari; Yasuhiro Mochizuki; Takao Hamakubo; Keiji Imoto; Dies Meijer; Masahiko Watanabe; Masaki Fukata
Journal:  Nat Med       Date:  2014-12-08       Impact factor: 53.440

Review 7.  Age matters.

Authors:  James Edgar McCutcheon; Michela Marinelli
Journal:  Eur J Neurosci       Date:  2009-03       Impact factor: 3.386

8.  Inactivation of LGI1 expression accompanies early stage hyperplasia of prostate epithelium in the TRAMP murine model of prostate cancer.

Authors:  John K Cowell; Karen Head; Padmaja Kunapuli; Mary Vaughan; Ellen Karasik; Barbara Foster
Journal:  Exp Mol Pathol       Date:  2009-09-22       Impact factor: 3.362

9.  Expression profile of Lgi1 gene in mouse brain during development.

Authors:  Patrícia A O Ribeiro; Lourenço Sbragia; Rovilson Gilioli; Francesco Langone; Fábio F Conte; Iscia Lopes-Cendes
Journal:  J Mol Neurosci       Date:  2008-06-18       Impact factor: 3.444

10.  ADAM22, a Kv1 channel-interacting protein, recruits membrane-associated guanylate kinases to juxtaparanodes of myelinated axons.

Authors:  Yasuhiro Ogawa; Juan Oses-Prieto; Moon Young Kim; Ido Horresh; Elior Peles; Alma L Burlingame; James S Trimmer; Dies Meijer; Matthew N Rasband
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.